Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.30 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.30 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.30 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.30 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.30 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.30 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27496418 | 0.98 | AKR1C2 (0.33) | AKR1C2AKR1C1CYP11B1CYP11B2 | |
| SCHEMBL1338710 | 0.81 | AKR1C2 (0.42) | AKR1C2AKR1C1CYP11B1CYP11B2PRKAB2 | |
| SCHEMBL9837416 | 0.78 | — | — | |
| SCHEMBL6776324 | 0.77 | — | — | |
| SCHEMBL1628206 | 0.75 | LMNA (0.35) | — | |
| SCHEMBL7774123 | 0.74 | L3MBTL1 (0.31) | — | |
| SCHEMBL2737141 | 0.74 | THRB (0.45) | — | |
| SCHEMBL8750439 | 0.74 | IDO1 (0.43) | AKR1C2AKR1C1 | |
| SCHEMBL12280720 | 0.74 | THRB (0.45) | — | |
| SCHEMBL57510 | 0.74 | THRB (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848379-B | Preparation method of carbonyl compound | 内蒙古民族大学 | 2022-10-04 | — | — | CN | claimed |
| CN-114516815-A | Controllable defluorination deuteration method for polyfluoroamide | 中国科学技术大学 | 2022-05-20 | — | — | CN | claimed |
| CN-111848379-A | Preparation method of carbonyl compound | 内蒙古民族大学 | 2020-10-30 | — | — | CN | claimed |
| CN-107074822-B | Triazole compounds as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | claimed |
| CN-106414429-B | Pyrazole compounds and their use as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | claimed |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-02 | — | — | US | claimed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | claimed |
| EP-3194374-B1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-08-01 | — | — | EP | claimed |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-19 | — | — | US | claimed |
| US-9932314-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-03 | — | — | US | claimed |
| EP-3152199-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | Actelion Pharmaceuticals Ltd. (CH) | 2017-04-12 | — | — | EP | claimed |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-06 | — | — | US | claimed |
| US-9499558-B2 | Compounds and methods for treating HIV | PURDUE RESEARCH FOUNDATION (US) | 2016-11-22 | — | — | US | claimed |
| WO-2016041892-A1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-24 | — | — | WO | claimed |
| WO-2015186056-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-10 | — | — | WO | claimed |
| US-20150225414-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-13 | — | — | US | claimed |
| US-9024038-B2 | Compunds and methods for treating HIV | PURDUE RESEARCH FOUNDATION (US) | 2015-05-05 | — | — | US | claimed |
| US-20130289067-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | PURDUE RESEARCH FOUNDATION | 2013-10-31 | — | — | US | claimed |
| US-6509426-B2 | Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability | JAPAN POLYCHEM CORPORATION (JP) | 2003-01-21 | — | — | US | claimed |
| EP-0334164-B1 | Antihypertensive combination preparation | HOFFMANN LA ROCHE (CH) | 1993-10-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | AKR1C2 2036/4885AKR1C1 1412/4885CYP11B1 474/4885 |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | CACNA1I, CACNA1E, CACNA1G | AKR1C2 1937/4885AKR1C1 1382/4885CYP11B1 566/4885 |
| US-20150225414-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | SERPINB1, HPN, DNPEP | AKR1C2 2108/4885AKR1C1 2055/4885CYP11B1 1802/4885 |
| US-20130289067-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | SERPINB1, HPN, DNPEP | AKR1C2 2108/4885AKR1C1 2055/4885CYP11B1 1802/4885 |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | AKR1C2 2036/4885AKR1C1 1412/4885CYP11B1 474/4885 |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | AKR1C2 2036/4885AKR1C1 1412/4885CYP11B1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.